...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >Radiotherapy is effective in patients with glioblastoma multiforme with a limited prognosis and in patients above 70 years of age: a retrospective single institution analysis.
【24h】

Radiotherapy is effective in patients with glioblastoma multiforme with a limited prognosis and in patients above 70 years of age: a retrospective single institution analysis.

机译：放射疗法对预后有限的多形性胶质母细胞瘤患者和70岁以上的患者有效：回顾性单一机构分析。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND AND PURPOSE: To evaluate the efficacy of radiotherapy in patients with glioblastoma multiforme (GBM) with a limited prognosis and in patients older than 70 years. PATIENTS AND METHODS: Retrospective analysis of 202 patients with GBM treated between 1990 and 2000 in a single institution. Patients (including patients >or=70 years) were assigned to RPA groups and their survival was compared with RTOG data. RESULTS: Median survival was 8.0 months for the total group and 13.9, 10.6, 3.8, 2.1 months for RPA group III (n=17), IV (n=87), V (n=60) and VI (n=38), respectively. Median survival for patients >or=70 years was 3.6 vs. 8.1 months for 50--70 years and 11.0 months for <50. In each separate RPA group, patients >or=70 years had a similar survival compared to patients of 50--70 years. Irradiated patients (66%) survived significantly longer than non-irradiated patients: 10.6 vs. 1.9 months (P<0.0001). In RPA group V the median survival for irradiated patients was 9.4 vs. 2.1 months for non-irradiated patients. In a multivariate analysis, RT remained the only prognostic factor for survival (HR 8.9, P<0.001). CONCLUSIONS: Prognosis for patients above 70 years of age is not different from younger patients, when analyzed for separate RPA groups. For patients with a poor prognosis (i.e. RPA group V), radiotherapy improves survival significantly.
机译：背景与目的：评价放射疗法对预后有限的多形性胶质母细胞瘤（GBM）患者和70岁以上患者的疗效。患者与方法：回顾性分析1990年至2000年间在单一机构中治疗的202例GBM患者。将患者（包括≥70岁的患者）分配到RPA组，并将其生存率与RTOG数据进行比较。结果：RPA组的中位生存期分别为8.0个月和13.9、10.6、3.8、2.1个月（n = 17），IV（n = 87），V（n = 60）和VI（n = 38） ， 分别。 ≥70岁的患者的中位生存期为50--70年为3.6个月，而8.1个月为<50岁的中位生存期为11.0个月。在每个独立的RPA组中，> 50岁或70岁以上的患者生存率均高于或等于70岁。受辐照的患者（66％）比未接受辐照的患者存活时间长得多：10.6比1.9个月（P <0.0001）。在RPA组V中，接受辐照的患者的中位生存期为9.4，而未接受辐照的患者为2.1个月。在多变量分析中，RT仍然是生存的唯一预后因素（HR 8.9，P <0.001）。结论：对单独的RPA组进行分析时，年龄在70岁以上的患者与年轻患者的预后没有区别。对于预后较差的患者（即RPA V组），放疗可显着提高生存率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号